{"product_id":"infusystem-five-forces-analysis","title":"InfuSystem Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eInfuSystem faces moderate buyer power and regulatory pressures, while supplier concentration and substitute therapies shape its competitive landscape—this snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore InfuSystem’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Medical Device Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary supply of infusion pumps is controlled by a handful of large medtech firms—BD (Becton Dickinson), Baxter, and ICU Medical—who together held roughly 60–70% of the US infusion pump market in 2024. Because InfuSystem depends on these specific brands to service and grow its rental fleet, those suppliers can push higher OEM prices and limit immediate availability, squeezing margins. Any further consolidation—several announced M\u0026amp;A talks continued into late 2025—would boost supplier leverage and reduce InfuSystem’s ability to secure favorable procurement terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Parts and Maintenance Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of proprietary infusion-pump parts hold strong leverage: InfuSystem must buy OEM components to meet FDA and EU MDR rules, raising switching costs and procurement concentration; in 2024 InfuSystem reported 68% of repair parts sourced from branded OEMs. This scarcity of generic biomedical parts tightens supplier bargaining power and can raise parts price volatility and service margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Standards Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers must follow strict FDA rules and ISO 13485 quality-management standards to supply medical-grade infusion equipment; noncompliant vendors risk bans and recalls. InfuSystem relies on a small pool of validated vendors—estimated under 20 core suppliers in 2024—who pass audits and traceability demands. That limits alternatives and raises bargaining power for certified suppliers, pushing supplier-side price pressure and longer lead times for InfuSystem.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Global Supply Chain Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobal logistics and geopolitics drive availability of semiconductors and medical-grade plastics; in 2025 global chip shortages eased but lead times remain 12–20 weeks for specialty components, letting suppliers push price increases onto service firms like InfuSystem.\u003c\/p\u003e\n\u003cp\u003eInfuSystem’s SLA-driven need for on-time delivery amplifies supplier leverage; a 5–15% surge in raw-material costs can compress gross margin given limited vertical integration and single-source parts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChip lead times: 12–20 weeks (2025)\u003c\/li\u003e\n\u003cli\u003eRaw-material cost shock: +5–15% impacts margins\u003c\/li\u003e\n\u003cli\u003eHigh SLA reliance increases supplier negotiating power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships and Exclusive Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExclusive distribution deals can block InfuSystem from leading with new infusion pumps; in 2024, 22% of US infusion device suppliers reported exclusive partnerships that restrict third-party servicers.\u003c\/p\u003e\n\u003cp\u003eIf a supplier partners with a direct competitor, InfuSystem’s market share and service revenue (InfuSystem reported $78.9M revenue in 2024) face pressure from reduced device access and higher switching costs.\u003c\/p\u003e\n\u003cp\u003eThese alliances let suppliers set entry points and pricing, raising barriers and concentrating supply power in the infusion services market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExclusive deals limit tech access—22% supplier exclusivity (2024)\u003c\/li\u003e\n\u003cli\u003ePartnering with rivals cuts revenue potential—InfuSystem $78.9M (2024)\u003c\/li\u003e\n\u003cli\u003eSuppliers influence market entry and pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier dominance threatens InfuSystem: shortages, exclusivity risk $78.9M revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power: 60–70% market share (BD, Baxter, ICU Medical, 2024), 68% OEM parts reliance (InfuSystem, 2024), \u003cbr\u003echip lead times 12–20 weeks (2025) and raw-material shocks +5–15% squeeze margins; 22% supplier exclusivity (2024) limits access and can cut InfuSystem’s $78.9M revenue base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop suppliers share\u003c\/td\u003e\n\u003ctd\u003e60–70% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM parts reliance\u003c\/td\u003e\n\u003ctd\u003e68% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChip lead times\u003c\/td\u003e\n\u003ctd\u003e12–20 weeks (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRaw-material shock\u003c\/td\u003e\n\u003ctd\u003e+5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier exclusivity\u003c\/td\u003e\n\u003ctd\u003e22% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfuSystem revenue\u003c\/td\u003e\n\u003ctd\u003e$78.9M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for InfuSystem, this Porter's Five Forces overview uncovers key competitive drivers, buyer\/supplier influence, entry barriers, substitutes, and emerging threats shaping its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-sheet for InfuSystem that highlights supplier, buyer, competitive, substitute, and entrant pressures—ideal for rapid strategic decisions and slide-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant share of InfuSystem’s revenue comes from large oncology practices and hospital networks that buy through Group Purchasing Organizations (GPOs), which bundle volume to demand lower prices and stricter contract terms.\u003c\/p\u003e\n\u003cp\u003eGPO-driven purchasing raised customer leverage: by 2025 roughly 70% of U.S. hospital procurement was GPO-influenced, concentrating negotiating power and pressuring InfuSystem’s margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Insurance Reimbursement Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInfuSystem’s customers rely on Medicare and private payers for most infusion reimbursement; Medicare cuts of 3.4% to infusion-related payments in 2024 put acute pressure on provider margins, per CMS updates, so providers push cost reductions onto vendors. When payers lower rates, InfuSystem must prove measurable savings—like shorter chair time or reduced readmissions—to retain contracts instead of competing only on device price. In 2025, with outpatient infusion volumes down ~2% industry-wide, pricing leverage for large providers increases, raising customer bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Integrated Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInfuSystem reduces buyer power by embedding its biomedical services and fleet-management software into clinic workflows, raising switching costs; clients using the full suite face operational disruption and retraining expenses often exceeding 6–12 months of lost productivity. In 2024 InfuSystem reported 78% recurring service revenue, reflecting contract stickiness that offsets pricing pressure. This deep integration makes customers less price-sensitive and increases retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Comprehensive Connectivity Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern hospitals demand infusion pumps that integrate with EHRs; 72% of US hospitals reported interoperability as a purchase driver in 2024, so customers push InfuSystem to fund continuous software updates and cybersecurity upgrades.\u003c\/p\u003e\n\u003cp\u003eCustomers gain leverage because missed connectivity features risk churn to competitors; InfuSystem’s FY2024 R\u0026amp;D spend of $8.7M signals where investment must go to retain contracts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e72% of US hospitals cite interoperability (2024)\u003c\/li\u003e\n\u003cli\u003eInfuSystem R\u0026amp;D: $8.7M in FY2024\u003c\/li\u003e\n\u003cli\u003eCybersecurity upgrades raise OPEX and switching costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative Equipment Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLarge hospitals can buy infusion pumps—US hospital capex for devices was about $7.2B in 2024—so infusing (insourcing) limits InfuSystem’s pricing power for managed-service rentals.\u003c\/p\u003e\n\u003cp\u003eHospitals with in-house biomedical teams (median staff 6–12 techs per 250 beds) can avoid rental fees, forcing InfuSystem to sell uptime, logistics, and compliance savings not just hardware.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapex constraint: $7.2B US device spend (2024)\u003c\/li\u003e\n\u003cli\u003eStaffing: 6–12 biomed techs\/250 beds\u003c\/li\u003e\n\u003cli\u003eImplication: pricing ceiling on rental contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfuSystem squeezed: GPO power and Medicare cuts pressure margins despite sticky services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers wield high leverage: ~70% of hospital procurement was GPO-influenced by 2025, pressuring InfuSystem margins; Medicare cuts of 3.4% in 2024 and a ~2% drop in outpatient infusion volume in 2025 increased buyer price sensitivity. InfuSystem’s 78% recurring service revenue and $8.7M R\u0026amp;D in FY2024 raise switching costs via integrated services, but $7.2B hospital device capex (2024) and biomed teams (6–12 techs\/250 beds) cap rental pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO influence (2025)\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare infusion cut (2024)\u003c\/td\u003e\n\u003ctd\u003e3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient infusion volume (2025)\u003c\/td\u003e\n\u003ctd\u003e−2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecurring service revenue (InfuSystem, 2024)\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (InfuSystem, FY2024)\u003c\/td\u003e\n\u003ctd\u003e$8.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospital device capex (2024)\u003c\/td\u003e\n\u003ctd\u003e$7.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomed techs per 250 beds\u003c\/td\u003e\n\u003ctd\u003e6–12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eInfuSystem Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact InfuSystem Porter's Five Forces Analysis you'll receive immediately after purchase—no placeholders or mockups. The document displayed here is the full, professionally formatted report, ready for download and use the moment you buy. You're viewing the final deliverable: comprehensive, actionable, and identical to the file you’ll get upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747550048633,"sku":"infusystem-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/infusystem-five-forces-analysis.png?v=1772199756","url":"https:\/\/matrixbcg.com\/products\/infusystem-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}